戚丽霜，博士，哈尔滨医科大学生物信息科学与技术学院副教授，博士研究生导师，星联教师。主要从事肺癌系统生物学及临床转化研究，已成功识别了肺腺癌微转移标志、铂类耐药预测标志等。研究成果以第一/通讯作者在《Briefings in bioinformatics》、《British journal of cancer》等国际期刊发表研究论文17篇。主持国家自然科学基金面上项目和青年项目各1项，黑龙江省卫生计生委科研课题基金1项，哈尔滨医科大学创新研究资助基金1项。获国家发明专利1项。指导本科生参与各级各类学科竞赛，获大学生创新创业训练计划项目国家级重点领域项目资助一项，美国大学生数学建模竞赛二等奖两项等。
个人邮箱：
qilishuang7@ems.hrbmu.edu.cn
学习和工作经历：
2017年9月--至今 哈尔滨医科大学 副教授
2014年7月-- 2016年9月 哈尔滨医科大学 讲师
2006年9月-- 2014年7月 哈尔滨医科大学 基础八年制
主持科研项目及人才计划项目情况：
1.国家自然科学基金面上项目，81872396，胃癌转移相关的基因标志的可重复性评价及再识别，2019/01-2022/12，在研，主持。
2.国家自然科学基金青年科学基金项目，61701143，肿瘤治疗方案多决策节点的个体化多级预后预测标志识别策略，2018/01-2020/12，结题，主持。
3.黑龙江省卫生计生委科研课题基金项目，肺腺癌个体化铂类耐药预测标志的识别，2017/01-2018/12，结题，主持。
4.哈尔滨医科大学创新研究资助项目，肿瘤治疗方案多决策节点的个体化多级预后预测标志识别策略，2017/06-2019/05，结题，主持。
学术兼职：
1.黑龙江省医师学会肺癌专业委员会，常务委员。
2．中国抗癌协会肿瘤标志专业委员会肿瘤测序及大数据分析专家委员会，委员。
3．中国抗癌协会肿瘤标志专业委员会肿瘤标志物临床转化研究协作组，委员。
发明专利和奖项：
1.《基于影像组学定性算法构建癌症临床指标评估系统》，2022年，国家发明专利，第一申请人。
2.《基于影像组学定性算法构建癌症临床指标评估系统》，2021年，大学生创新创业计划项目，国家级重点领域项目，指导教师。
3.《癌症协同扰动模块分析方法研究及其预后标志识别》，2020年，黑龙江省医药卫生科学技术二等奖，第二完成人。
4.《非可控性炎症向癌症转化的分子机制研究》，2017年,黑龙江省科学技术奖三等奖，第三完成人。
5.《融合组学挖掘非可控性炎症向癌症转化的分子机制》，2016年,哈尔滨市科学技术进步三等奖，第三完成人。
发表的科研论文：
1. Bo Chen#, Pengfei Li#, Mingyue Liu#, Kaidong Liu, Min Zou, Yiding Geng, Shuping Zhuang, Huanhuan Xu, Linzhu Wang, Tingting Chen, Yawei Li, Zhangxiang Zhao,Lishuang Qi*,Yunyan Gu*. A genetic map of the chromatin regulators to drug response in cancer cells.Journal of Translational Medicine, 2022 Sep 30;20(1):438.
2. Xin Li#, Lefan Tang#, Jiaxing Deng, Xiuying Qi, Juxuan Zhang, Haitao Qi, Mengyue Li, Yixin Liu, Wenyuan Zhao, Yunyan Gu,Lishuang Qi*and Xia Li*. Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis.Communications Biology,2022 Mar 17;5(1):198.
3. Yixin Liu#, Haitao Qi#, Chunni Wang, Jiaxing Deng, Yilong Tan, Lin Lin, Zhirou Cui, Jin Li* andLishuang Qi*. Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer via Computed Tomography Derived Radiomic Features.Frontiers in Oncology, 2022 Jun 22;12:832343.
4. Juxuan Zhang1#, Jiaxing Deng1#, Xiao Feng, Yilong Tan, Xin Li, Yixin Liu, Mengyue Li, Haitao Qi, Lefan Tang, Qingwei Meng, Haidan Yan* andLishuang Qi*. Hierarchical identification of a transcriptional panel for the histological diagnosis of lung neuroendocrine tumors.Frontiers in Genetics, 2022 Aug 29;13:944167.
5. Zheyang Zhang#, Sainan Zhang#, Xin Li, Zhangxiang Zhao, Changjing Chen, Juxuan Zhang, Mengyue Li, Zixin Wei, Wenbin Jiang, Bo Pan, Ying Li, Yixin Liu, Yingyue Cao, Wenyuan Zhao, Yunyan Gu , Yan Yu*, Qingwei Meng* andLishuang Qi*. Reference genome and annotation updates lead to contradictory prognostic predictions in gene expression signatures: a case study of resected stage I lung adenocarcinoma.Briefings in Bioinformatics, 2021 May 20;22(3):bbaa081.
6.Yixin Liu#, Jin Li#, Wenlei Dong, Yang Zhou, Kuan Luan*,Lishuang Qi*.Identifying 18F-FDG P ET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module.Quantitative Imaging in Medicine and Surgery, 2022 Mar;12(3):1893-1908.
7. Bo Pan#, Zi Xin Wei#, Ju Xuan Zhang#, Xin Li, Qing Wei Meng, Ying Yue Cao,Lishuang Qi*, and Yan Yu*.The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.Am J Transl Res,2021 May 15;13(5):4464-4476.
8. Huarong Zhang#, Xiangyu Li#, Junling Wu, Jiahui Zhang, Haiyan Huang, Yawei Li, Meifeng Li, Shanshan Wang, Jie Xia,Lishuang Qi*, Ting Chen* and Lu Ao*.A qualitative transcriptional signature of recurrence risk for stages II–III gastric cancer patients after surgical resection.J Gastroenterol Hepatol, 2021 Sep;36(9):2501-2512.
9.Yidan Shi#,Lishuang Qi#, Haifeng Chen, Jiahui Zhang, Qingzhou Guan, Jun He1, Meifeng Li1, Zheng Guo, Haidan Yan, Ping Li.Identification of Genes Universally Differentially Expressed in Gastric Cancer,Biomed Research International, 2021 Jan 21;2021:7326853.
10.Ying Li#, Wenbin Jiang#, Tianhao Li, Mengyue Li, Xin Li, Zheyang Zhang, Sainan Zhang, Yixin Liu,Wenyuan Zhao, Yunyan Gu,Lishuang Qi*, Lu Ao* and Zheng Guo*.Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.Journal of Translational Medicine, 2020 Jan 14;18(1):25.
11.Yelin Fu#,Lishuang Qi#, Wenbing Guo, Liangliang Jin, Kai Song, Tianyi You, Shuobo Zhang, Yunyan Gu, Wenyuan Zhao* and Zheng Guo*. A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer.BMC Genomics, 2019, 20:769
12. Xin Li, Gengen Shi, Qingsong Chu, Wenbin Jiang, Yixin Liu, Sainan Zhang, Zheyang Zhang, Zixin Wei, Fei He, Zheng Guo* andLishuang Qi*.A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas.BMC Genomics, 2019 Nov 21;20(1):881.
13．Yixin Liu#, Zheyang Zhang#, Tianhao Li, Xin Li, Sainan Zhang, Ying Li, Wenyuan Zhao, Yunyan Gu, Zheng Guo* andLishuang Qi*.A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy.Frontiers in Oncology, 2019 Oct 18;9:1094.
14. Haidan Yan#, Hao Cai#, Qingzhou Guan, Jun He, Juan Zhang, You Guo, Haiyan Huang, Xiangyu Li, Yawei Li, Yunyan Gu,Lishuang Qi*and Zheng Guo*. Individualized analysis of differentially expressed miRNAs with application to the identification of miRNAs deregulated commonly in lung cancer tissues.Briefings in Bioinformatics, 2018 Sep 28;19(5):793-802.
15.Lishuang Qi#, Tianhao Li#, Gengen Shi, Jiasheng Wang, Xin Li, Sainan Zhang, Libin Chen, Yuan Qin, Yunyan Gu, Wenyuan Zhao and Zheng Guo*. An individualized gene expression signature for prediction of lung adenocarcinoma metastases.Molecular Oncology, 2017 Nov;11(11):1630-1645.
16.Lishuang Qi, Libin Chen, Yang Li, Yuan Qin, Rufei Pan, Wenyuan Zhao, Yunyan Gu, Hongwei Wang, Ruiping Wang, Xiangqi Chen*and Zheng Guo*.Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer.Briefings in Bioinformatics,2016 Mar; 17(2):233-42.
17.Lishuang Qi#, Yang Li#, Yuan Qin, Gengen Shi, Tianhao Li, Jiasheng Wang, Libin Chen, Yunyan Gu, Wenyuan Zhao*and Zheng Guo*. An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.British Journal of Cancer, 2016 Dec 6;115(12):1513-1519.
